Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...
The MarketWatch News Department was not involved in the creation of this content. -- Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results